user avatar
Formation Bio
@formationbio
AI-native pharma company, bringing new treatments to patients faster and more efficiently.
New York, NY
Joined November 2014
Posts
  • Pinned
    user avatar
    The world has more promising discovered drug candidates than ever. The problem is developing them. We built Formation Bio to fix that, using AI to develop drugs faster and with a higher likelihood of success. Thank you @amyfeldman and @Forbes telling the story of our mission,
  • user avatar
    Thrilled to announce that @23andMe and TrialSpark are collaborating to reimagine clinical trials and achieve a common end-goal: accelerate the pace, quality, and experience of clinical trials. Learn more and submit your proposal today: trialspark.com/rfp
    Image
  • user avatar
    Today we announce our $372MM Series D financing, led by @a16z with major participation from @sanofi, advancing our mission to bring new treatments to patients faster and more efficiently. Read more here!
  • user avatar
    We're super excited to share that TrialSpark has raised a $156M Series C to support our mission to bring new treatments to patients faster and more efficiently.
  • user avatar
    Check out @nikillinit of TrialSpark's Strategic Partnerships team w/ @eriktorenberg & @malayhgandhi on a recent episode of @villageglobal's Venture Stories podcast. They talk startup innovation, strategy, & challenges in the healthcare space. Listen here:
  • user avatar
    We’re proud to take one small step in the ongoing, lifelong work of combating racism, intolerance, and injustice in our country by recognizing Juneteenth as an official annual company holiday. blog.trialspark.com/trialspark-hon…
    Image
  • user avatar
    There are several thousand known human diseases, yet we only have FDA-approved treatments for about 500 of them. Our CEO Benjamine Liu explains what we at Trialspark are doing to tackle that challenge — and how you can get involved.
  • user avatar
    TrialSpark is proud to announce the launch of Project Covalence, a platform that will allow sponsors to rapidly launch clinical trials for COVID-19. Learn more: projectcovalence.com
    Image
  • user avatar
    Dr. Michael Mina of the Harvard T.H. Chan School of Public Health enrolled 500 patients in a COVID-19 serological surveillance study in just ten days using TrialSpark’s Covalence trial platform. Learn more about our partnership: prnewswire.com/news-releases/…
    Image
  • user avatar
    We are excited to announce our collaboration with @OpenAI & @sanofi to build fine-tuned and custom AI solutions to transform drug development, advancing our mission to bring new treatments to patients faster and more efficiently.
  • user avatar
    Pleased to share news about our collaboration @Pfizer. Read more about how we're working together to increase access to #clinicaltrials: prnewswire.com/news-releases/…
    Image
  • user avatar
    Join our CEO, @BenjamineYLiu, at the #CNSSummit tomorrow morning to learn more about the work TrialSpark is doing to improve the speed, quality, and innovation of #clinicaltrials.
    Image
  • user avatar
    @TrialSpark has licensed sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from @merckgroup. Read more here about the transaction and TrialSpark's mission to bring new treatments to patients faster. prn.to/33vXmN3
  • user avatar
    Our Head of Data, Ilan Man, shares some advice for the aspiring data scientist. Check out our careers page or drop us a comment here if you're interested in joining our Data team.